((Sara M. Tinsley, Ph.D., ARNP, AOCN))
Because neutrophils and platelets may take longer to recover after treatment with VYXEOS, granulocyte-colony stimulating factor and platelet transfusions may be given to assist recovery.
For a patient whose counts have not recovered, we see them twice a week until fully recovered.
During their visits, we look for bleeding and signs of infection and we administer blood transfusions as required.
Generally, we look for patients to have fewer than 5% blasts before granulocyte-colony stimulating factor is given to aid with recovery, but this may vary by institution.
VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t‑AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
IMPORTANT SAFETY INFORMATION